Mumbai, India — April 28, 2026
Investors are closely watching the upcoming earnings of Piramal Pharma Limited, as the company’s board met on Tuesday to consider its financial results for the fourth quarter of fiscal year 2025–26. As of now, the detailed results are yet to be officially released.
Q4 Expectations: Modest Profit, Stable Margins
According to market estimates, Piramal Pharma’s net profit is expected to range between ₹28 crore and ₹55 crore, while revenue is projected between ₹2,400 crore and ₹2,600 crore.
Analysts expect the company’s EBITDA margin to remain in the range of 16% to 19%, reflecting stable operational performance in a competitive pharmaceutical environment.
The company has scheduled an earnings call on April 29, 2026, at 9:30 AM, where management is expected to provide further insights into performance and outlook.
Piramal Finance Delivers Strong Results
Meanwhile, the group’s financial services arm, Piramal Enterprises Limited, reported robust earnings for the same quarter.
- Net profit surged 390% year-on-year to ₹502 crore
- Assets Under Management (AUM) crossed ₹1 lakh crore for the first time
The strong performance triggered a positive market reaction, with shares of Piramal Enterprises rising over 10% intraday, reflecting investor optimism.
Market Focus on Pharma Segment
While Piramal Finance’s results have boosted sentiment, the spotlight now remains on Piramal Pharma’s official numbers. Investors are keen to assess growth trends, margin stability, and future guidance.
